Search

Your search keyword '"Antilymphocyte Serum"' showing total 1,610 results
Start Over Descriptor "Antilymphocyte Serum" Publication Year Range Last 10 years
1,610 results on '"Antilymphocyte Serum"'

7. Diabetes Islet Preservation Immune Treatment (DIPIT)

Author

Diabetes Research Institute Foundation and Camillo Ricordi and Jay Skyler, Professors, University of Miami Miller School of Medicine and Director/Deputy Director, Diabetes Research Institute

Published
2024

11. A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (TransIT)

Author

Center for International Blood and Marrow Transplant Research, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Pediatric Aplastic Anemia Consortium, Pediatric Transplantation and Cellular Therapy Consortium, Blood and Marrow Transplant Clinical Trials Network, and David Williams, Chief - Division of Hematology/Oncology

Published
2024

40. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination.

Author

Asashima, Hiromitsu, Kim, Dongjoo, Wang, Kaicheng, Lele, Nikhil, Buitrago-Pocasangre, Nicholas, Lutz, Rachel, Cruz, Isabella, Raddassi, Khadir, Ruff, William, Racke, Michael, Wilson, JoDell, Givens, Tara, Grifoni, Alba, Sette, Alessandro, Kleinstein, Steven, Montgomery, Ruth, Shaw, Albert, Li, Fangyong, Fan, Rong, Hafler, David, Tomayko, Mary, Longbrake, Erin, and Weiskopf, Daniela

Subjects
Autoimmune diseases, Autoimmunity, COVID-19, Multiple sclerosis, Humans, Aged, Antibody Formation, SARS-CoV-2, BNT162 Vaccine, COVID-19, Vaccination, Antibodies, Monoclonal, Antilymphocyte Serum, RNA, Messenger
Abstract

BACKGROUNDWhile B cell depletion is associated with attenuated antibody responses to SARS-CoV-2 mRNA vaccination, responses vary among individuals. Thus, elucidating the factors that affect immune responses after repeated vaccination is an important clinical need.METHODSWe evaluated the quality and magnitude of the T cell, B cell, antibody, and cytokine responses to a third dose of BNT162b2 or mRNA-1273 mRNA vaccine in patients with B cell depletion.RESULTSIn contrast with control individuals (n = 10), most patients on anti-CD20 therapy (n = 48) did not demonstrate an increase in spike-specific B cells or antibodies after a third dose of vaccine. A third vaccine elicited significantly increased frequencies of spike-specific non-naive T cells. A small subset of B cell-depleted individuals effectively produced spike-specific antibodies, and logistic regression models identified time since last anti-CD20 treatment and lower cumulative exposure to anti-CD20 mAbs as predictors of those having a serologic response. B cell-depleted patients who mounted an antibody response to 3 vaccine doses had persistent humoral immunity 6 months later.CONCLUSIONThese results demonstrate that serial vaccination strategies can be effective for a subset of B cell-depleted patients.FUNDINGThe NIH (R25 NS079193, P01 AI073748, U24 AI11867, R01 AI22220, UM 1HG009390, P01 AI039671, P50 CA121974, R01 CA227473, U01CA260507, 75N93019C00065, K24 AG042489), NIH HIPC Consortium (U19 AI089992), the National Multiple Sclerosis Society (CA 1061-A-18, RG-1802-30153), the Nancy Taylor Foundation for Chronic Diseases, Erase MS, and the Claude D. Pepper Older Americans Independence Center at Yale (P30 AG21342).

Published
2023

47. Preemptive Therapy of GVHD

Author

University of Alberta, Alberta Health services, and Jan Storek, Professor of Medicine

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results